AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18349272
Drug: Supplemental alpha-tocopherol
RxNorm normalized name: alpha tocopherol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental alpha-tocopherol (50 mg/d) and/or beta-carotene (20 mg/d)
Trial: 1281650
Drug: Initial chemotherapy
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial chemotherapy with sequential methotrexate‐5‐FU with leucovorin rescue (MFL) for 6 months
Trial: 1281650
Drug: Primary expectancy
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary expectancy with chemotherapy only after the appearance of symptoms
Trial: 31027883
Drug: Sevelamer (1,600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sevelamer (1,600 mg thrice daily) for 3 months
Trial: 31027883
Drug: Sevelamer treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sevelamer treatment
Trial: 24671450
Drug: TAK-442 (pooled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-442 (pooled doses)
Trial: 24671450
Drug: TAK-442 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-442 (various doses)
Trial: 21809603
Drug: Injectable lidocaine
RxNorm normalized name: lidocaine Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable lidocaine 2% solution (1.5 ml)
Trial: 21809603
Drug: Topical lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lidocaine 2% gel (1.5 ml)
Trial: 18413426
Drug: 2,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2,000 IU oral vitamin D2 daily
Trial: 18413426
Drug: 50,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50,000 IU vitamin D2 weekly
Trial: 18413426
Drug: 2,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2,000 IU vitamin D3 daily
Trial: 11831538
Drug: ERA-923 (10-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ERA-923 (10-200 mg)
Trial: 1682643
Drug: monocomponent pertussis
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: monocomponent pertussis toxoid vaccine
Trial: 1682643
Drug: two-component acellular
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two-component acellular vaccine also containing filamentous haemagglutinin
Trial: 1682643
Drug: 20% albumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% albumin solution (placebo)
Trial: 6756799
Drug: Oxipor VHC
RxNorm normalized name: Oxipor VHC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxipor VHC lotion
Trial: 6756799
Drug: Tegrin lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegrin lotion
Trial: 24351402
Drug: 10% urea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% urea cream (arm B)
Trial: 17476705
Drug: Tiagabine 4-16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiagabine 4-16 mg per day for 12 weeks
Trial: 15148924
Drug: Levofloxacin, Chinese
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin, Chinese traditional medicine and microwave
Trial: 9536926
Drug: NG‐monomethyl L‐arginine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NG‐monomethyl L‐arginine (3 mg h‐1 kg‐1)
Trial: 1990984
Drug: Generic topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic topical steroids
Trial: 1990984
Drug: Trade-name topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trade-name topical steroids
Trial: 6337004
Drug: Epoprostenol (PGI2)
DrugBank: Epoprostenol (DB01240)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoprostenol (PGI2) infusion at doses of 2, 4, 6, and 8 ng/kg/min
Trial: 6337004
Drug: Dipyridamole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole (400 mg/day for 3 days)
Trial: 24893962
Drug: 400 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 μg of sublingual misoprostol
Trial: 31926328
Drug: Minimally invasive
RxNorm normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimally invasive treatment (endoscopic approach)
Trial: 31926328
Drug: Conventional Bascom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Bascom cleft lift treatment
Trial: 31926328
Drug: Cost analysis
RxNorm normalized name: Chemicals and reagents for analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cost analysis of minimally invasive treatment
Trial: 24190860
Drug: High-dose n-3
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose n-3 PUFA (Lovaza 3600 mg/day)
Trial: 24190860
Drug: Low-dose n-3
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose n-3 PUFA (Lovaza 900 mg/day)
Trial: 17337426
Drug: Sildenafil citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil citrate 100 mg oral treatment
Trial: 15778966
Drug: Three-dose hepatitis
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-dose hepatitis B vaccination course (Engerix B GlaxoSmithKline) administered at 0, 1, and 12 months; adult dose containing 20 mug recombinant hepatitis B surface antigen in 1 ml suspension.
Trial: 9295239
Drug: Isoniazid daily
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoniazid daily for six months
Trial: 9295239
Drug: Isoniazid and
RxNorm normalized name: Isoniazid and rifampin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoniazid and rifampin daily for three months
Trial: 9295239
Drug: Isoniazid, rifampin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoniazid, rifampin, and pyrazinamide daily for three months
Trial: 7509573
Drug: Structured sensorimotor
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured sensorimotor therapy
Trial: 3539030
Drug: 20 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 micrograms intranasal DDAVP
Trial: 30149145
Drug: SGLT2 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SGLT2 inhibitors (dapagliflozin)
Trial: 20236776
Drug: Vaginal oestradiol
RxNorm normalized name: estradiol Vaginal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal oestradiol (25 micrograms, Vagifem, Novo Nordisk) once daily for 2 weeks, then twice weekly for 6 months (group 1)
Trial: 12872170
Drug: Thiopental, nitrous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental, nitrous oxide, and low-dose isoflurane
Trial: 8927680
Drug: Zotepine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zotepine (150 to 300 mg)
Trial: 8927680
Drug: Haloperidol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (10 to 20 mg)
Trial: 1294919
Drug: Transdermal fentanyl
RxNorm normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Transdermal fentanyl 70-80 micrograms/hr
Trial: 1294919
Drug: Transdermal fentanyl
RxNorm normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Transdermal fentanyl 90-100 micrograms/hr
Trial: 1294919
Drug: Intramuscular morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular morphine 150 micrograms/kg every 6h
Trial: 6364994
Drug: 1% sulconazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% sulconazole cream
Trial: 6364994
Drug: 2% miconazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% miconazole cream
Trial: 18035195
Drug: Ibutilide 0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibutilide 0.01 mg/kg
Trial: 18035195
Drug: Ibutilide 0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibutilide 0.02 mg/kg
Trial: 18035195
Drug: Ibutilide 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibutilide 0.5 mg
Trial: 18035195
Drug: Ibutilide 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibutilide 0.75 mg
Trial: 18035195
Drug: Ibutilide 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibutilide 1.0 mg
Trial: 12042266
Drug: Trilostane 1080
RxNorm normalized name: TRILOSTANE
DrugBank: Trilostane (DB01108)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trilostane 1080 mg
Trial: 12042266
Drug: Trilostane 720
RxNorm normalized name: TRILOSTANE
DrugBank: Trilostane (DB01108)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trilostane 720 mg
Trial: 10214664
Drug: New corticosteroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New corticosteroid drug
Trial: 7833731
Drug: Metformin (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (in obese subjects)
Trial: 2226910
Drug: Norethindrone 1
RxNorm normalized name: norethindrone 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norethindrone 1 mg/mestranol 0.05 mg/d (group A)
Trial: 31159548
Drug: Negative pressure
RxNorm normalized name: DRESSING,NEGATIVE PRESSURE WOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative pressure wound therapy with automated instillation
Trial: 31159548
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard negative pressure therapy)
Trial: 27513627
Drug: iPad administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: iPad administration of ICIQ questionnaires
Trial: 27513627
Drug: Telephone administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telephone administration of ICIQ questionnaires
Trial: 27513627
Drug: Paper administration
RxNorm normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paper administration of ICIQ questionnaires
Trial: 25533601
Drug: Progressive resistance
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Progressive resistance exercise program (3 sets of 10 to 12 leg extensions at 70% of estimated 1-repetition maximum thrice weekly for 8 weeks)
Trial: 20078697
Drug: One-step self-etch
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One-step self-etch bonding agent
Trial: 20078697
Drug: Two-step total-etch
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two-step total-etch bonding agent
Trial: 15672116
Drug: High calcium
RxNorm normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High calcium and normal protein (HC/NP: 1800 mg calcium, 15% of energy from protein)
Trial: 15672116
Drug: Low calcium
RxNorm normalized name: Dianeal Low Calcium 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low calcium and normal protein (LC/NP: 500 mg calcium, 15% of energy from protein)
Trial: 15672116
Drug: High calcium
RxNorm normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High calcium and high protein (HC/HP: 1800 mg calcium, 23% of energy from protein)
Trial: 8708586
Drug: Intensive advice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive advice (no drug)
Trial: 8708586
Drug: Usual advice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual advice (no drug)
Trial: 6813126
Drug: NTG-TTS (transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NTG-TTS (transdermal therapeutic system for nitroglycerin)
Trial: 19110786
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg clopidogrel maintenance dose
Trial: 19110786
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg clopidogrel maintenance dose (control)
Trial: 17130267
Drug: Nonatorvastatin therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonatorvastatin therapy
Trial: 12939009
Drug: Single-stage implants
RxNorm normalized name: SAGE
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-stage implants with screw-retained restorations
Trial: 12939009
Drug: Single-stage implants
RxNorm normalized name: SAGE
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-stage implants with cemented restorations
Trial: 12939009
Drug: Single-stage implants
RxNorm normalized name: SAGE
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-stage implants in completely edentulous patients
Trial: 12939009
Drug: Single-stage implants
RxNorm normalized name: SAGE
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-stage implants in partially edentulous patients
Trial: 11039684
Drug: Child‐focused cognitive‐behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Child‐focused cognitive‐behaviour therapy (CBT)
Trial: 6661342
Drug: Propranolol administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol administration during exercise
Trial: 28990807
Drug: Internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive behavioural therapy for tinnitus
Trial: 20061838
Drug: Gabapentin in
RxNorm normalized name: Product containing gabapentin in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin in combination therapy with two antihistamines
Trial: 20061838
Drug: Chlorpheniramine in
RxNorm normalized name: chlorpheniramine Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpheniramine in combination with two antihistamines
Trial: 16984938
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (60 mg daily for the first week and 40 mg daily for the second week)
Trial: 12944994
Drug: Adjuvant cytotoxic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant cytotoxic therapy
Trial: 8949825
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of edrophonium 1 mg kg‐1 and exogenous PCHE equivalent to activity present in 25 ml kg‐1 of human plasma
Trial: 8949825
Drug: Edrophonium 1
RxNorm normalized name: edrophonium 10 mg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edrophonium 1 mg kg‐1 (group ED)
Trial: 8949825
Drug: Exogenous PCHE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exogenous PCHE equivalent to activity present in 25 ml kg‐1 of human plasma (group PCHE)
Trial: 8949825
Drug: Edrophonium 1
RxNorm normalized name: edrophonium 10 mg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edrophonium 1 mg kg‐1 and exogenous PCHE (combination group)
Trial: 7014073
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg doxpicomine
Trial: 31833868
Drug: Heparin prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin prophylaxis during the third trimester
Trial: 31833868
Drug: No antepartum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antepartum heparin prophylaxis
Trial: 31301146
Drug: Adjunctive PAD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive PAD (red LED, 635 nm, photosensitive dye, 0.01% tolonium chloride)
Trial: 31301146
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no adjunctive PAD)
Trial: 31301146
Drug: Adjunctive PAD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive PAD
Trial: 28160084
Drug: N‐3 PUFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N‐3 PUFA (2330 mg day‐1)
Trial: 27969041
Drug: Daily journal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily journal writing as reinforcement for resourcefulness training (RT) over a four-week period.
Trial: 22406990
Drug: BMS +
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BMS + high-dose oral sirolimus (initial dose of 15 mg, followed by 6 mg/day for four weeks)
Trial: 22406990
Drug: BMS +
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BMS + low-dose sirolimus (6 mg followed by 2 mg daily for four weeks)
Trial: 22406990
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (BMS + high-dose sirolimus, BMS + low-dose sirolimus, BMS without sirolimus)
Trial: 19054608
Drug: Botulinum neurotoxin
RxNorm normalized name: Botulinum neurotoxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum neurotoxin type A (BoNTA) treatment
Trial: 9829604
Drug: Continuous nasogastric
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous nasogastric infusion of liquid feeding (4.2 kJ/mL, energy provision 1 x the initial predicted basal metabolic rate; 3 days)
Trial: 9829604
Drug: Continuous nasogastric
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous nasogastric infusion of colored water (2 days)
Trial: 9829604
Drug: Continuous nasogastric
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous nasogastric infusion of liquid feeding (4.2 kJ/mL)
Trial: 2780070
Drug: Ketanserin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin (10 mg for upper limb pain, 20 mg for lower limb pain)
Trial: 25732032
Drug: Palliative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palliative treatment (use of aspirin and analgesics only, no reperfusion)
Trial: 25732032
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (any treatment including antithrombotics or anticoagulants, but no reperfusion)
Trial: 25732032
Drug: Reperfusion treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reperfusion treatment (thrombolysis and/or percutaneous coronary intervention)
Trial: 23788306
Drug: Intracoronary (IC)
RxNorm normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary (IC) bolus of GP IIb/IIIa inhibitor
Trial: 23788306
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) bolus of GP IIb/IIIa inhibitor
Trial: 19187417
Drug: Occupational and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational and physical therapy sessions to instruct participants in compensatory strategies, home modifications, home safety, fall recovery techniques, and balance and muscle strength exercises.
Trial: 15885050
Drug: Tolperisone (300-900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolperisone (300-900 mg daily)
Trial: 11408847
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate (6-g load then 2 g/hr)
Trial: 9312708
Drug: Metal implants
RxNorm normalized name: menthone 1,2-glycerol ketal, (-)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metal implants
Trial: 9312708
Drug: Polyactide implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyactide implants
Trial: 8358527
Drug: Intramuscular interferon‐alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular interferon‐alpha
Trial: 8358527
Drug: CO2 laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CO2 laser ablation plus intramuscular interferon‐alpha
Trial: 3117084
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate (SCG) administered to the nasal mucosa 30 min before provocation with histamine
Trial: 3117084
Drug: Clemastine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clemastine administered to the nasal mucosa 30 min before provocation with histamine
Trial: 3117084
Drug: Ketotifen administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen administered to the nasal mucosa 30 min before provocation with histamine
Trial: 3117084
Drug: Placebo (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline control solution) administered prior to provocation
Trial: 3117084
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate (SCG), clemastine, and ketotifen administered to the nasal mucosa 30 min before provocation with allergen
Trial: 17925050
Drug: Slow-release vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release vitamin C tablets (500 mg/d) and vitamin E (182 mg/d) for 4 weeks
Trial: 17925050
Drug: Well-nourished subjects
RxNorm normalized name: Lantiseptic Nourishing Skin
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Well-nourished subjects consuming 600 g fruits and vegetables or equivalent vitamins and minerals for 24 days
Trial: 16194620
Drug: Supervised aerobic
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Supervised aerobic and resistance training program twice a week for five months
Trial: 10786405
Drug: Sertaconazole monodose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertaconazole monodose vaginal suppository only (group O)
Trial: 10786405
Drug: Sertaconazole monodose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertaconazole monodose vaginal suppository combined with sertaconazole cream applied to the vulvar area for 7 days (group OC)